Adjuvant Therapy Using Dabrafenib plus Trametinib in Chinese Patients with Resected Stage III Melanoma: A Multicenter Retrospective Cohort Study

IF 3.7 4区医学 Q1 DERMATOLOGY

Dermatologic Therapy Pub Date : 2024-05-24 DOI:10.1155/2024/9952950

Dong-Dong Jia, Yu Xu, Ting Li, Ji-Long Yang, Yong Chen, Tao Li

{"title":"Adjuvant Therapy Using Dabrafenib plus Trametinib in Chinese Patients with Resected Stage III Melanoma: A Multicenter Retrospective Cohort Study","authors":"Dong-Dong Jia, Yu Xu, Ting Li, Ji-Long Yang, Yong Chen, Tao Li","doi":"10.1155/2024/9952950","DOIUrl":null,"url":null,"abstract":"<div>\n Background. In patients with stage III melanoma carrying BRAF mutations, the risk of melanoma recurrence is relatively high even after complete resection of the primary melanoma and regional lymph nodes. Methods. We collected data from patients with stage III cutaneous and acral melanoma who received adjuvant trametinib combined with dabrafenib from three cancer centres in China between August 2019 and December 2022. Results. A total of 55 patients were included in this study. The one-year recurrence-free survival (RFS) rate was 79.8% (95% CI 73.6–86.0%). The one-year RFS rate was 79.8% (95% CI 72.8–86.8%) in the cutaneous melanoma subgroup, while the one-year RFS rate was 74.1% (95% CI 58.0–90.2%) in the acral melanoma subgroup. Six (46.2%) patients experienced recurrence during adjuvant therapy; 7 (53.9%) patients recurred after completion of the regimen. At the time of the first recurrence, distant metastasis occurred in 10 patients, local recurrence occurred in 2 patients, and one patient experienced both distant metastasis and local recurrence. Conclusions. This study confirmed the good tolerability and short-term benefits of adjuvant therapy with dabrafenib and trametinib in Chinese patients with stage III melanoma with BRAF V600 mutation.\n </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2024 1","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/9952950","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2024/9952950","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background. In patients with stage III melanoma carrying BRAF mutations, the risk of melanoma recurrence is relatively high even after complete resection of the primary melanoma and regional lymph nodes. Methods. We collected data from patients with stage III cutaneous and acral melanoma who received adjuvant trametinib combined with dabrafenib from three cancer centres in China between August 2019 and December 2022. Results. A total of 55 patients were included in this study. The one-year recurrence-free survival (RFS) rate was 79.8% (95% CI 73.6–86.0%). The one-year RFS rate was 79.8% (95% CI 72.8–86.8%) in the cutaneous melanoma subgroup, while the one-year RFS rate was 74.1% (95% CI 58.0–90.2%) in the acral melanoma subgroup. Six (46.2%) patients experienced recurrence during adjuvant therapy; 7 (53.9%) patients recurred after completion of the regimen. At the time of the first recurrence, distant metastasis occurred in 10 patients, local recurrence occurred in 2 patients, and one patient experienced both distant metastasis and local recurrence. Conclusions. This study confirmed the good tolerability and short-term benefits of adjuvant therapy with dabrafenib and trametinib in Chinese patients with stage III melanoma with BRAF V600 mutation.

Abstract Image

查看原文本刊更多论文

在中国切除的III期黑色素瘤患者中使用达拉非尼和曲美替尼进行辅助治疗：一项多中心回顾性队列研究

背景。在携带 BRAF 基因突变的 III 期黑色素瘤患者中，即使完全切除了原发黑色素瘤和区域淋巴结，黑色素瘤复发的风险也相对较高。研究方法我们收集了中国三个癌症中心在2019年8月至2022年12月期间接受曲美替尼联合达拉非尼辅助治疗的III期皮肤黑色素瘤和尖锐湿疣患者的数据。研究结果本研究共纳入55例患者。一年无复发生存率（RFS）为79.8%（95% CI 73.6-86.0%）。皮肤黑色素瘤亚组的一年无复发生存率为79.8%（95% CI 72.8-86.8%），而口腔黑色素瘤亚组的一年无复发生存率为74.1%（95% CI 58.0-90.2%）。6名患者（46.2%）在辅助治疗期间复发；7名患者（53.9%）在完成治疗后复发。首次复发时，10 名患者出现远处转移，2 名患者出现局部复发，1 名患者同时出现远处转移和局部复发。结论。该研究证实，达拉非尼和曲美替尼辅助治疗中国BRAF V600突变的III期黑色素瘤患者具有良好的耐受性和短期疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatologic Therapy 医学-皮肤病学

CiteScore

7.00

自引率

8.30%

发文量

711

审稿时长

3 months

期刊介绍： Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.